Cabaletta Bio, Inc. (NASDAQ: CABA)
$2.4350
+0.1250 ( +7.27% ) 849.8K
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Market Data
Open
$2.4350
Previous close
$2.3100
Volume
849.8K
Market cap
$117.31M
Day range
$2.1960 - $2.5100
52 week range
$1.7600 - $26.3500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 77 | Nov 18, 2024 |
10-q | Quarterly Reports | 63 | Nov 14, 2024 |
8-k | 8K-related | 13 | Nov 14, 2024 |
8-k | 8K-related | 37 | Oct 07, 2024 |
8-k | 8K-related | 11 | Sep 30, 2024 |
10-q | Quarterly Reports | 57 | Aug 08, 2024 |
8-k | 8K-related | 39 | Aug 08, 2024 |
8-k | 8K-related | 85 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 04, 2024 |
def | Proxies and info statements | 12 | Apr 23, 2024 |